Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Hepatitis and Liver Cancer
The global epidemic of hepatitis B and C is a serious public health problem. Hepatitis B and C are the major causes of chronic liver disease and liver cancer in the world. In the next 10 years, 150,000 people in the United States will die from liver disease or liver cancer associated with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. Today, between 800,000 and 1.4 million people in the United States have chronic hepatitis B and between 2.7 and 3.9 million have chronic hepatitis C. People most at risk for hepatitis B and C often are the least likely to have access to medical services. Reducing the rates of illness and death associated with these diseases will require ...
Hepatitis and Liver Cancer
The global epidemic of hepatitis B and C is a serious public health problem. Hepatitis B and C are the major causes of chronic liver disease and liver cancer in the world. In the next 10 years, 150,000 people in the United States will die from liver disease or liver cancer associated with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. Today, between 800,000 and 1.4 million people in the United States have chronic hepatitis B and between 2.7 and 3.9 million have chronic hepatitis C. People most at risk for hepatitis B and C often are the least likely to have access to medical services. Reducing the rates of illness and death associated with these diseases will require ...
A National Strategy for the Elimination of Hepatitis B and C
Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the second of two, builds off the conclusions of the first report and outlines a strategy for hepatitis reduction over time and specific actions to achieve them.
Viral Hepatitis
None
Viral Hepatitis in Children
This book is aimed to emphasize the rationale and importance of prevention and management of viral hepatitis in children, providing cutting edge knowledge. Viral hepatitis is a major health problem in the world. Although most complications of viral hepatitis are observed in adults, primary infection with hepatitis viruses often occurs during infancy or childhood. To better control viral hepatitis, prevention and therapy if possible should be started in childhood. This book offers updated and unique information about viral hepatitis in children, which has vitally important impact on global disease outcome and control, yet not discussed as frequently as viral hepatitis in adults in previous me...
Guidelines for the Prevention Care and Treatment of Persons with Chronic Hepatitis B Virus Infection
These are the first World Health Organization (WHO) guidelines for theprevention care and treatment of persons living with CHB infection andcomplement similar recent published guidance by WHO on the prevention care and treatment of infection due to the hepatitis C virus (HCV). In contrastto several recent international guidelines on the management of CHB infectionfrom the United States Europe Asia-Pacific and the United Kingdom (UK) theprimary audience for these WHO guidelines is country programme managers inall settings but particularly in LMICs to help plan the development and scale up.
Eliminating the Public Health Problem of Hepatitis B and C in the United States
Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the first of two, examines the feasibility of hepatitis B and C elimination in the United States and identifies critical success factors. The phase two report will outline a strategy for meeting the elimination goals discussed in this report.
Viral Hepatitis: Acute Hepatitis
This book presents up-to-date, practically oriented information on major topics in acute hepatitis. The coverage encompasses epidemiology; diagnosis, including molecular methods; treatment and challenges; and the management of co-infections. The book opens by examining the local and global epidemiology of acute hepatitis. Detailed attention is then paid to each of acute hepatitis A, acute hepatitis B, acute hepatitis C, hepatitis D co-infection, and hepatitis E. Acute Hepatitis will be of high value for general practitioners and specialists in gastroenterology, infectious diseases, and internal medicine. It will be international in scope in terms of both authorship and appeal.
Viral Hepatitis
The 4th edition of Viral Hepatitis covers comprehensively the entire complex field of infections caused by all of the different hepatitis viruses, which affect many millions of people throughout the world with considerable morbidity and mortality. Howard Thomas and Arie Zuckerman are joined by Anna Lok from the USA and Stephen Locarnini from Australia as Editors. They have recruited leading researchers and physicians from many countries, who have produced an authoritative account of current knowledge and research on this important infection, including new insights into immune response to HBV and HCV. The result is a comprehensive account on all aspects of viral hepatitis, including rapid adv...
